Learning ObjectivesAt the end of this session, participants will be able to:To understand the incredible advancements that continue to be made in the management of age related macular degeneration.Appreciate how to select the best therapeutic option to minimize vision loss in macular degeneratio...

Learning ObjectivesAt the end of this session, participants will be able to:To understand the new therapeutic options available for the management of DME and how these will impact clinical practiceAppreciate how to select the best therapeutic option to minimize vision loss in DME...

Author’s Name(s): Nirojini Sivachandran, Stela Vujosevic, Christiana Dinah, Roger Goldberg, Michael Ip, Ehsan Rahimy, Manuel Amador, Kara Gibson, Carl Glittenberg, Andreas MaunzAuthor’s Disclosure Block: Nirojini Sivachandran: Roche, Employment/honoraria/consulting fees, Bayer, Employment/honoraria/consulting fees, Apellis, Employment/honoraria/consulting fees; Stela Vujosevic: Consultant: AbbVie/Allergan, Apellis, Bayer, Boehringer Ingelheim, Novartis...

Learning ObjectivesAt the end of this session, participants will be able to:To understand advancements in surgical management of retinal detachments    Evaluate new treatments for rare retinal conditions